Azitra, Inc.
@azitrainc
Followers
596
Following
620
Media
69
Statuses
473
Precision dermatology powered by microbial and genetic engineering Developing novel therapeutics to treat adverse skin conditions and disease
Branford, CT
Joined November 2015
There are reports circulating around Azitra with respect to issuance of stock by the company. These reports are false. Please refer to our IR page for official press releases and more information: https://t.co/ql6fjBhXZx $AZTR
ir.azitrainc.com
The Investor Relations website contains information about Azitra, Inc.'s business for stockholders, potential investors, and financial analysts.
4
4
8
Azitra, Inc. Addresses False Report Regarding Sale of Securities - @azitrainc $AZTR
ir.azitrainc.com
BRANFORD, Conn. , Nov. 7, 2025 /PRNewswire/ -- Azitra , Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology,...
1
1
9
More from our most recent announcement. @azitrainc Announces Positive Preclinical Data for ATR-01 Program, Designed to Treat Ichthyosis Vulgaris. Read the release here: https://t.co/jk0fZ1G1Yn
#RareDisease #Dermatology #IchthyosisVulgaris $AZTR
3
2
11
Last week, we announced positive preclinical progress for our ATR-01 ichthyosis vulgaris program. For more info about this rare skin condition, see the Foundation for Ichthyosis and Related Skin Types (FIRST) https://t.co/1XWIFHrLrN
#RareDisease #Dermatology #IchthyosisVulgaris
firstskinfoundation.org
Ichthyosis Vulgaris is considered one of the five main types of ichthyosis.
0
0
0
In case you missed it - @DermTimesNow covered @azitrainc news earlier this week: Azitra's ATR-01 Shows Promise in Preclinical Studies for Ichthyosis Vulgaris https://t.co/Xbq0c12wzl
#biotech #RareDisease #Derm #Dermatology #PrecisionDerm #IchthyosisVulgaris #BIOEurope $AZTR
dermatologytimes.com
Azitra reveals promising preclinical results for ATR-01, a novel treatment targeting ichthyosis vulgaris, paving the way for future clinical trials.
1
0
1
Great coverage in @DermTimesNow highlighting our ATR-01 program in ichthyosis vulgaris! https://t.co/Xbq0c12wzl
#biotech #RareDisease #Derm #IchthyosisVulgaris #BIOEurope $AZTR
dermatologytimes.com
Azitra reveals promising preclinical results for ATR-01, a novel treatment targeting ichthyosis vulgaris, paving the way for future clinical trials.
0
0
2
@azitrainc Announces Positive Preclinical Data for ATR-01 Program, Designed to Treat Ichthyosis Vulgaris https://t.co/jk0fZ1Fu8P Data to be presented at BIO-Europe! #biotech #RareDisease #Derm #Dermatology #PrecisionDerm #IchthyosisVulgaris #BIOEurope $AZTR
ir.azitrainc.com
ATR-01, which uses a filaggrin-secreting strain of S. epidermidis , is in preclinical development for ichthyosis vulgaris Preclinical data show production of active, functional filaggrin delivered...
1
0
0
Yesterday's announcement in case you missed it - @azitrainc to Participate in Dermatologic Rare Disease Panel at Maxim Growth Summit - #biotech #RareDisease #Dermatology #PrecisionDerm @MaximGrp $AZTR More info here: https://t.co/rfIaWIw9vN
@azitrainc to Participate in Dermatologic Rare Disease Panel at Maxim Growth Summit - #biotech #RareDisease #Dermatology #PrecisionDerm @MaximGrp $AZTR https://t.co/WtCldaw6xe
0
0
1
@azitrainc to Participate in Dermatologic Rare Disease Panel at Maxim Growth Summit - #biotech #RareDisease #Dermatology #PrecisionDerm @MaximGrp $AZTR https://t.co/WtCldaw6xe
prnewswire.com
/PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision...
0
0
1
About us: @azitrainc is leveraging microbial & protein engineering to solve the challenges of skin diseases through 3 strategies: -Proprietary microbial library -Engineering microbes for drug delivery -Advance genetic engineering Learn more: https://t.co/jA4P59greS $AZTR
0
0
1
@azitrainc - Developing a broad pipeline of precision dermatology products. Learn about our #pipeline here https://t.co/knzrzvg511
#biotech #NethertonSyndrome #EGFRirash #Dermatology #PrecisionDerm #IchthyosisVulgaris
0
0
0
Throwing it back to a recent #podcast interview our CEO Francisco Salva did with #EmpoweredPatient Addressing the Skin Microbiome with Topical Engineered Microbes Available here
podcasts.apple.com
Podcast Episode · Empowered Patient Podcast · 05/29/2025 · 20m
Looking for podcast listen for the holiday weekend? Check out the #EmpoweredPatient #Podcast - Addressing the Skin Microbiome with Topical Engineered Microbes with Francisco Salva, CEO of @azitrainc
https://t.co/VUvoPBFUFI
#RareDisease #NethertonSyndrome #CancerRash
0
0
0
We recently announced the 1st patient dosed in our Phase 1/2 trial for the ATR-04 program targeting oncology Patients with EGFRi associated rash. Learn more about our approach - engineering microbes for microbial #DrugDelivery for #PrecisionDermatology – https://t.co/l8dbarLsEN
@azitrainc Announces First Patient Dosed in Phase 1/2 Trial for ATR-04 Program Targeting Oncology Patients with EGFRi-Associated Rash #CancerRash #EGFRirash #PrecisionDerm #ClinicalTrials #Biotech $AZTR https://t.co/FtDwoIARyV
0
1
1
Reminder that @azitrainc Cofounder and Chief Operating Officer, Travis Whitfill PhD MPH, delivered a virtual presentation at the H.C. Wainwright 27th Annual Global Investment Conference Registration info: https://t.co/GV8Arm3tFT
#biotech #HCWainwright #PrecisionDerm
@azitrainc to Present at the H.C. Wainwright 27th Annual Global Investment Conference - more details available here $AZTR
0
0
0
Last week we announced that the first patient had been dosed in our Ph1/2 Trial for our ATR-04 Program targeting #oncology patients with #EGFRiRash. For more info on the trial - Check out this article from @CancerNetwrk
https://t.co/fCETT6ze5Z
cancernetwork.com
ATR04-484 showed inhibition of both methicillin-sensitive and methicillin-resistant Staphylococcus aureus bacteria strains, which are associated with rash.
@azitrainc Announces First Patient Dosed in Phase 1/2 Trial for ATR-04 Program Targeting Oncology Patients with EGFRi-Associated Rash #CancerRash #EGFRirash #PrecisionDerm #ClinicalTrials #Biotech $AZTR https://t.co/FtDwoIARyV
0
0
1
@azitrainc to Present at the H.C. Wainwright 27th Annual Global Investment Conference - more details available here $AZTR
ir.azitrainc.com
BRANFORD, Conn. , Sept. 4, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology,...
0
0
1
More from this morning's announcement. See the full release here - #CancerRash #EGFRirash #PrecisionDerm #ClinicalTrials #Biotech $AZTR https://t.co/FtDwoIARyV
2
0
0
@azitrainc Announces First Patient Dosed in Phase 1/2 Trial for ATR-04 Program Targeting Oncology Patients with EGFRi-Associated Rash #CancerRash #EGFRirash #PrecisionDerm #ClinicalTrials #Biotech $AZTR https://t.co/FtDwoIARyV
ir.azitrainc.com
BRANFORD, Conn. , Aug. 27, 2025 /PRNewswire/ -- Azitra, Inc. (" Azitra ") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision...
1
0
1
ICYMI - @azitrainc COO Travis Whitfill with Zack's John Vandermosten this week #PrecisionDerm #NethertonSyndrome #CancerRash #Pipeline #Biotech $AZTR
Just out - @azitrainc COO & Co-Founder Travis Whitfill spoke with John Vandermosten of Zack - providing updates on the progress of our ATR-12 & ATR-04 programs. #PrecisionDerm #NethertonSyndrome #CancerRash #Pipeline #Biotech $AZTR
2
0
1